High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
about
Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004Bleeding related to disturbed fibrinolysisTACTIC: Trans-Agency Consortium for Trauma-Induced CoagulopathyCellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.Influence of cellular and plasma procoagulant activity on the fibrin networkThe hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.Abnormal whole blood thrombi in humans with inherited platelet receptor defects.Fibrinolysis and the control of blood coagulation.Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplantEmpirical and theoretical phenotypic discrimination.Discordant fibrin formation in hemophilia.Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinkingBasic aspects of bypassing agents.Thrombin generation, fibrin clot formation and hemostasisThe influence of prophylactic factor VIII in severe haemophilia A.Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stabilityThrombin generation testing in haemophilia comprehensive care centres.Thrombin generation in hemorrhage control and vascular occlusion.Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin.The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.The nature of the stable blood clot procoagulant activities.Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause.Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.Altered Flow Changes Thrombin Generation Rate of Circulating Platelets.Fibrinogen and Fibrin in Hemostasis and Thrombosis.Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis.
P2860
Q24681461-85737013-B815-47CA-A51C-2E5889AFCF2BQ28070127-95EC445C-3B4A-4856-9AAC-5A207555B231Q28083939-9B168703-01AD-4768-81DE-9B21915EC92EQ33381505-51A08FAE-8822-493E-BCCC-720795BC7D3FQ33729536-3B58FF4F-0E03-4F76-8B3D-737E1679A15BQ33911771-C04F9923-A9B5-45E4-9E9D-65F62C444407Q33934481-FEFAE63F-E8DC-4530-9484-A3D3CAAEA007Q34541342-70664581-AA16-47A9-BD4F-E02FFAAF723BQ35039847-81436107-07E8-46F0-A0FC-455DD53BFA4FQ35167279-0463555B-D21D-41B3-860A-EE2EE091ADEDQ35690807-2C2F9B56-6772-4E41-986E-48A10E41AF54Q35924900-9200728E-E2EB-4EF4-A94F-EF1B427EDE4AQ36090193-D4E2AEB2-EEAE-446C-B47F-79FE2850B60AQ36105820-705F5A5B-93C3-420D-B43C-137164A69A2AQ36163331-AA627CDF-9D8A-4881-AAB3-9E93C08D2A7BQ36169271-0CE2CCDF-6236-481A-9F4F-E1D32AB47FB2Q36661832-3B98CAB5-4FB2-4558-820B-32A4679904CDQ36691794-5BFD6E5A-8ACD-413C-8415-643A80026A49Q37186732-8112A06D-7C02-468D-8057-7F4C87DAF3F9Q37450566-D0C7DE55-ADC9-46BE-B105-750D23B800A5Q37589662-7691E525-A90E-4E22-B2BB-A1A8F0B7B32BQ37900072-07C0EB75-6023-4C90-9981-D6C7567CCC41Q38546790-BEED29D8-8500-4A62-A69D-02E7B9DB93FCQ38928171-62725D03-06EA-48B9-877E-552CEE7B0FBDQ39117235-95DE6BAD-10C7-4940-B356-A325E50A7D17Q39420691-62D1ACEE-B4C6-4617-AF6C-CD367BC88C0DQ39646902-080C8D2C-F850-4DE1-9E68-5B0F816B55BDQ40942451-4A7DAACC-3C3A-4979-8A65-804DEC2B17A2Q42360054-550A711B-46AB-4A93-B9E6-AB764E433563Q44514782-7ACEAAEB-CD5E-4F81-BA87-A8054D9EB41EQ45168592-95E4D8FF-53A1-4F29-90F3-B3A3C3C89911Q45867938-3A9F7825-3109-4CFA-8CBE-AE0D85A4F573Q45868696-E2C049F1-7C13-463D-83B0-8832D58556A3Q45871220-1D3E2AD9-9612-4F87-9108-C05E9098CAF6Q45873682-DB6D7E9A-AA61-4FF4-9994-07F545BD4C4FQ45876598-E382F305-4CE8-4177-9356-6B61C4EE8537Q45877251-27D632F5-D050-4BFA-8A0D-CBB768D18EBDQ53480847-3226FBC0-ACE2-4583-BB63-105641B8E76FQ54842287-D111F56F-356B-4A6C-AC6F-5264EA685FE7Q55716954-F12A0BF2-C496-432D-BE4D-AAC0C58EC1EA
P2860
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@en
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@nl
type
label
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@en
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@nl
prefLabel
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@en
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@nl
P2093
P2860
P50
P1476
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
@en
P2093
Alisa S Wolberg
Harold R Roberts
Ulla Hedner
P2860
P304
P356
10.1111/J.1365-2141.2005.05820.X
P407
P577
2005-12-01T00:00:00Z